An official website of the United States government
Home
Name
SYNC-T SV-102
Alternate Names
None
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Prostate
Histology
None
Remarks
July 5, 2024 FDA granted Fast Track designation for SYNC-T SV-102 therapy, for the treatment of patients with metastatic castrate-resistant prostate cancer. SV-102 is an in situ personalized therapy that uniquely employs a combination multi-target approach to cancer treatment, aiming to improve outcomes and quality of life for patients.
Code as Other treatment
Code as Other treatment
Coding
Please see remarks for additional information
